Abstract:<h3 class="article-section__sub-title section1"> Objective</h3><p>While the role of antiphospholipid antibodies in activating endothelial cells has been extensively studied, the impact of these antibodies on the adhesive potential of leukocytes has received less attention. Here, we investigated the extent to which antiphospholipid syndrome (APS) neutrophils adhered to resting endothelial cells under physiologic flow conditions, as well as the surface molecules required for that adhesion.</p><h3 class="article-section__sub-title section1"> Methods</h3><p>Patients with primary APS (n=43), patients with history of venous thrombosis but negative testing for antiphospholipid antibodies (n=11), and healthy controls (n=38) were studied. Cells were introduced into a flow chamber and perfused across resting human umbilical vein endothelial cell (HUVECs). Surface adhesion molecules were quantified by flow cytometry. Neutrophil extracellular trap (NET) release (NETosis) was assessed in neutrophil‐HUVEC co‐cultures.</p><h3 class="article-section__sub-title section1"> Results</h3><p>Upon perfusion of anticoagulated blood through the flow chamber, APS neutrophils demonstrated increased adhesion as compared with control neutrophils under conditions representative of either venous (n=8, p<0.05) or arterial (n=15, p<0.0001) flow. At the same time, APS neutrophils were characterized by upregulation of CD64, CEACAM1, beta‐2 glycoprotein I, and activated Mac‐1 on their surface (n=12‐18, p<0.05 for all markers). Exposing control neutrophils to APS plasma or APS IgG resulted in increased neutrophil adhesion (n=10‐11, p<0.001) and surface marker upregulation as compared with controls. A monoclonal antibody specific for activated Mac‐1 reduced the adhesion of APS neutrophils in the flow‐chamber assay (p<0.01). The same monoclonal antibody reduced NETosis in neutrophil‐HUVEC co‐cultures (p<0.01).</p><h3 class="article-section__sub-title section1"> Conclusion</h3><p>APS neutrophils demonstrate increased adhesive potential, which is dependent upon the activated form of Mac‐1. In patients, this could lower the threshold for neutrophil‐endothelium interactions, NETosis, and possibly thrombotic events.</p><p>This article is protected by copyright. All rights reserved.</p>

Low ectonucleotidase activity and increased neutrophil-platelet aggregates in patients with antiphospholipid syndrome

Anti–Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome

Increased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by β2 Integrin Mac‐1

Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome

Calprotectin impairs platelet survival in patients with primary antiphospholipid syndrome

Neutrophil glucose flux as a therapeutic target in antiphospholipid syndrome

Altered platelet proteome in lupus anticoagulant (LA)-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis

Platelets and Thrombotic Antiphospholipid Syndrome

NEUT-RI, a surrogate marker of NETosis is lower in patients with strong IgM antiphospholipid antibodies

Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice

Targeting thromboinflammation in antiphospholipid syndrome

Oxidised low-density lipoprotein and antibodies against oxidised low-density lipoprotein in patients with antiphospholipid syndrome

Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome

A mutation of the human EPHB2 gene leads to a major platelet functional defect

Neutrophils—Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Insight into antiphospholipid syndrome: the role and clinical utility of neutrophils extracellular traps formation

Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome

An update on inflammation in antiphospholipid syndrome

Decreased hippocampal cell proliferation in mice with experimental antiphospholipid syndrome

Epigenetics-mediated pathological alternations and their potential in antiphospholipid syndrome diagnosis and therapy.

Antiphospholipid antibody‐activated NETs exacerbate trophoblast and endothelial cell injury in obstetric antiphospholipid syndrome